DavasaicinAlternative Names: capsavanil; DA 5018; KR 25018
Latest Information Update: 08 Nov 2002
At a glance
- Originator Korea Research Institute of Chemical Technology
- Developer Dong-A Pharmaceutical
- Class Non-opioid analgesics
- Mechanism of Action TRPV cation channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetic neuropathies; Neuralgia; Pain; Pruritus